Certificate of Compliance

(COC-0003, Rev 06)

This is to certify that BioTissue Holdings Inc. (parent company of BioTissue Surgical Inc. and BioTissue Ocular Inc., from hereon, collectively referred to as 'the Company') is a provider of 361 'Human Cells, Tissues and Cellular and Tissue Based Products' (HCT/Ps) for BioTissue Surgical. BioTissue Holdings Inc. meets the requirements of the United States Food & Drug Administration (FDA) for the manufacture and distribution of Neox® 100, Neox® 1K, Neox® RT, Neox® Flo, Clarix® 100, Clarix® 1K and Clarix® Flo (HCT/Ps) as specified in Current Good Tissue Practices (21 CFR Part 1271) & current AATB Standards. BioTissue Holdings Inc. certifies that:

- ✓ Neox® 100, Clarix® 100, Neox® 1K, Clarix® 1K, Neox® Flo, Clarix® Flo, and Neox® RT are regulated under 21 CFR 1271 and Section 361 of the Public Health Service Act (PHSA) and manufactured according to Current Good Tissue Practice (CGTP) and Current Good Manufacturing Practice (CGMP) regulations established by the US Food & Drug Administration (FDA).
- ✓ The Company is registered and inspected as a manufacturer and distributor with products listed with the FDA *(available upon request)*
- ✓ The Company is registered with Health Canada respecting the Safety of Human Cell Tissues and Organs for Transplantation for all BioTissue Surgical products, excluding Neox® Flo and Clarix® Flo *(available upon request)*

The Company is accredited by the American Association of Tissue Banks (AATB) *(available upon request)*

The Company is compliant with AATB standards and FDA requirements for tissue processing

- ✓ The Company is licensed by California and New York State Departments of Health *(available upon request)*

The Company is registered with Maryland, Illinois, and Oregon *(available upon request)*

The Company has been issued a waiver by the State of Florida exempting registration and certification as a tissue bank since the Company does not procure, process, store or distribute cadaveric tissue *(available upon request)*

Product Description:

- Neox® 100 and Clarix® 100 are cryopreserved human amniotic membrane products which are aseptically processed and cell devitalized. Neox® 100 and Clarix® 100 are delivered on a non-implantable, gridded paper backing for easier handling and application.
- Neox® 1K and Clarix® 1K are cryopreserved ultra-thick human amniotic membrane products derived from umbilical cord which are aseptically processed, devascularized and cell devitalized.
- Neox® 100, Clarix® 100, Neox® 1K and Clarix® 1K are manufactured, using the CryoTek® process, from donated human birth tissue acquired after elective C-section delivery.
- Neox® Flo and Clarix® Flo are sterile, micronized human amniotic membrane products derived from placenta and umbilical cord which are aseptically processed, cell devitalized and lyophilized. Neox® Flo and Clarix® Flo are manufactured from donated human birth tissue acquired after elective C- section delivery. Neox® Flo and Clarix® Flo are terminally sterilized via gamma irradiation with a Sterility Assurance Level (SAL) of 10^{-6}.
- Neox® RT is a sterile, ultra-thick human amniotic membrane product derived from umbilical cord which

is aseptically processed and cell devitalized. Neox® RT is manufactured from donated human birth tissue acquired after elective C-section delivery. Neox® RT is terminally sterilized via gamma irradiation with a Sterility Assurance Level (SAL) of 10^{-6}.

- The cells of these tissues have been devitalized to reduce the possibility of graft rejection while retaining the natural biologic properties.
- There is no pooling of tissues from different donors throughout the manufacturing process.

Tissue Place of Origin: Human amniotic membrane and umbilical cord tissues are only retrieved from donors within the United States who have donated tissue after elective Cesarean Section delivery.

- ✓ The Company acquires birth tissue (placenta, amniotic membrane and umbilical cord) through an internal acquisition program or contracts directly with FDA-registered acquisition partners *(available upon request)*
- ✓ Tissue is acquired after elective C-section from mothers birthing live, healthy babies

Donor Suitability, Selection & Testing:

- This tissue was procured from a donor determined to be eligible based on the results of donor screening and testing. HCT/P donor eligibility and placenta suitability, which is based on the results of donor screening at delivery for infectious, malignant, neurological & auto-immune diseases and for other exposures or social habits, has been determined and documented by BioTissue Holdings Inc..
- A blood specimen, drawn within ± 7 days of donation, has undergone serological testing by a laboratory registered with the FDA to perform donor testing and certified to perform such testing on human specimens in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and 42 CFR Part 493, or that has met equivalent requirements as determined by the Centers for Medicare and Medicaid Services (CMS). The donor has been tested for the following infectious diseases and results were non-reactive:

  - HIV-1 & HIV-2 Antibody
  - HIV-1 (RNA-NAT)
  - Hepatitis B Surface Antigen (HBsAg)
  - Hepatitis B Core Antibody (HBcAb)
  - Hepatitis B (HBV, DNA-NAT)
  - Hepatitis C Antibody (HCVAb)
  - Hepatitis C Virus, HCV (RNA-NAT)
  - Syphilis (RPR)
  - HTLV I & II Antibody (HTLV I/II Ab)
  - West Nile Virus (WNV, RNA-NAT)

Process Controls: Final product is processed for BioTissue Surgical in the Company's GMP Clean Room Facility using aseptic methods under ISO Class 5 Biological Safety Cabinets. Final product (Neox® 100, Neox® 1K, Clarix® 100 and Clarix® 1K) is tested by an independent CLIA-certified lab and is released after microbiological testing for aerobic, anaerobic and fungal organisms shows no growth. Final product (Neox® RT, Neox® Flo and Clarix® Flo) is released after sterilization by gamma irradiation to a Sterility Assurance Level (SAL) of 10^{-6}. Additionally, technical review and Quality Assurance review and approval is performed before product release. Process validations of aseptic processing, container closure integrity testing of the final packaging system, final product sterilization (for Neox® RT, Neox® Flo and Clarix® Flo products), and antimicrobial effectiveness of the final packaging system have been performed and found the systems and processes to be acceptable.

Labeling & Traceability: Each finished product (HCT/P) is assigned and labeled with a unique identification code that relates the final product to the donor. There is a system established and maintained to track the final product from the consignee to the donor and from the donor to the consignee or final disposition.

CryoTek® CRYOPRESERVED PRODUCTS

Stability (Cold Storage): BioTissue Surgical's amniotic membrane products (Neox® 100 and Clarix® 100) and ultra-thick amniotic membrane products derived from umbilical cord (Neox® 1K and Clarix ® 1K) are preserved in validated and patented storage solutions. Validation studies have been conducted to establish the expiration date of these amniotic membrane products and ultra-thick amniotic membrane products derived from umbilical cord when stored between -80°C - 4°C and the results are reflected in the storage requirements established for these products. Validation studies include analysis of tissue sections followed by morphological staining of test and control tissue samples, as well as package and container closure integrity testing of final packaging systems.

Packaging/Shipping (Cold Storage): See individual Product Inserts for packaging information. The shipping containers have been validated via simulated and actual shipping condition testing. These studies also provide objective evidence that the package integrity is maintained throughout transit therefore providing sufficient protection to the product during the transportation process.

Storage (Cold Storage): BioTissue Surgical's amniotic membrane products (Neox® 100 and Clarix® 100) and ultra-thick amniotic membrane products derived from umbilical cord (Neox® 1K and Clarix® 1K) are stored at cold temperature storage before shipping to retain their natural function and integrity. These cryopreserved amniotic membrane products and ultra-thick amniotic membrane products derived from umbilical cord are shipped in a shipper validated to hold the required temperature during shipping. Upon receipt, ensure the validated time on the shipper has not expired. Remove the product and store accordingly until use.

Location & Temperature	Use After Receipt
-80°C – 4°C (-112°F – 39.2°F) Example: ultra-low temperature freezer, standard freezer, or standard refrigerator	Within the expiration date printed on product packaging (shelf-life is 2 years from date of manufacture)

Amniotic membrane products and ultra-thick amniotic membrane products derived from umbilical cord exposed to controlled room temperature (20°C - 25°C, 68°F - 77°F) for up to 6 hours may be returned to cold temperature storage (-80°C - 4°C, -112°F - 39.2°F) in accordance with the storage table above as long as the packaging remains unopened and intact.

STERILE MICRONIZED PRODUCTS

Stability (Ambient): BioTissue Surgical's sterile, micronized human amniotic membrane products derived from placenta and umbilical cord (Neox® Flo and Clarix® Flo) are packaged and sealed in a validated final packaging system. The tissue has been stored at ambient room temperature prior to distribution. Validation studies have been conducted to establish the expiration date of these micronized human amniotic membrane products derived from placenta and umbilical cord at ambient storage and those results are reflected in the storage requirements established for these products. Validation studies included analysis of the product integrity of test and control tissue samples.

Packaging/Shipping (Ambient): See individual Product Inserts for packaging information. The shipping containers have been validated via simulated transit testing. The validating studies concluded that the shipping containers currently in use by BioTissue Surgical for final product distribution and ambient shipment effectively maintain package integrity throughout the transit, thereby providing sufficient protection to the product during the transportation process.

Storage (Ambient): BioTissue Surgical's sterile, micronized human amniotic membrane products derived from placenta and umbilical cord (Neox® Flo and Clarix® Flo) are gamma irradiated to an SAL of 10^{-6} and stored at ambient room temperature before shipping. These sterile, micronized human amniotic membrane products derived from placenta and umbilical cord are shipped in validated shipping containers. Upon receipt, remove the product from the shipper and store
accordingly until use.

Location & Temperature	Use After Receipt
Ambient Room Temperature 0°C - 38.0°C (32.0°F - 100.4°F)	Until the expiration date printed on outer product packaging (shelf-life is 2 years from date of manufacture)

SteriTek® STERILE ROOM TEMPERATURE PRODUCT

Stability (Room Temperature): BioTissue Surgical's sterile, ultra-thick human amniotic membrane product derived from umbilical cord (Neox® RT) is packaged and sealed in a validated final packaging system. The tissue has been stored in controlled room temperature prior to distribution. Validation studies have been conducted to establish the expiration date and sterility assurance level (SAL) of 10^{-6} of the ultra-thick human amniotic membrane product derived from umbilical cord at controlled room temperature; those results are reflected in the storage and sterility requirements established for the product. Validation studies included analysis of the product integrity of test and control tissue samples.

Packaging/Shipping (Room Temperature): See individual Product Inserts for packaging information. The shipping containers have been validated via simulated transit testing. The validation studies concluded that the shipping containers currently in use by BioTissue Surgical for final product distribution and shipment effectively maintain package integrity throughout the transit, thereby providing sufficient protection to the product during the transportation process.

Storage (Room Temperature):

Location & Temperature	Use After Receipt
Controlled Room Temperature 20°C - 25°C (68°F - 77°F)	Within the expiration date printed on product packaging (shelf-life is 2 years from date of manufacture)

Voluntary Correction/Removal Procedures: The Company has detailed procedures in place to respond appropriately to product concerns that may affect the health and safety of the patient. The current tracking system facilitates any correction or removal event that may occur. All affected customers will be immediately notified by verbal or electronic communication. Formal written notification will also be issued.

Refer to BioTissue Surgical's Individual Product Inserts for more details.

DocuSigned by:
Eden Venti
Signer Name: Eden Venti
Signing Reason: I approve this document
Signing Time: 04/27/23 | 10:37 AM EDT
90BDEFBC8F0B44AD81541A695E914553

04/28/23 | 12:24 PM EDT

Eden Venti
Vice President of Quality
BioTissue Holdings Inc.

Date

DocuSign

Certificate Of Completion

Envelope Id: 679D449CDED14FB6BF9F56463BACE5A8
Status: Completed
Subject: Complete with DocuSign: COC-0003 Rev. 06.docx
Source Envelope:
Document Pages: 5
Signatures: 1
Certificate Pages: 1
Initials: 0
AutoNav: Enabled
EnvelopeId Stamping: Enabled
Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Envelope Originator:
Katia Izquierdo
7300 Corporate Center Drive
Suite 700
Miami, FL 33122-1934
kIzquierdo@BioTissue.com
IP Address: 170.55.57.34

Record Tracking

Status: Original
4/27/2023 10:14:14 AM
Holder: Katia Izquierdo
kIzquierdo@BioTissue.com
Location: DocuSign

Signer Events	Signature	Timestamp
Eden Venti eventi@biotissue.com VP, QA BioTissue Holdings Inc. Security Level: Email, Account Authentication (Required)	Eden Venti Signature Adoption: Pre-selected Style Signature ID: 90BDEFBC-8F0B-44AD-8154-1A695E914553 Using IP Address: 170.55.57.34 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 4/27/2023 10:15:54 AM Viewed: 4/27/2023 10:37:09 AM Signed: 4/28/2023 12:24:40 PM

Electronic Record and Signature Disclosure:
Not Offered via DocuSign

In Person Signer Events	Signature	Timestamp

Editor Delivery Events	Status	Timestamp

Agent Delivery Events	Status	Timestamp

Intermediary Delivery Events	Status	Timestamp

Certified Delivery Events	Status	Timestamp

Carbon Copy Events	Status	Timestamp

Witness Events	Signature	Timestamp

Notary Events	Signature	Timestamp

Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	4/27/2023 10:15:54 AM
Certified Delivered	Security Checked	4/27/2023 10:37:09 AM
Signing Complete	Security Checked	4/28/2023 12:24:40 PM
Completed	Security Checked	4/28/2023 12:24:40 PM

Payment Events	Status	Timestamps